Page last updated: 2024-12-08

nla 1

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

NLA 1: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	368824
CHEMBL ID	541282
SCHEMBL ID	8909002
MeSH ID	M0196794

Synonyms (17)

Synonym
140448-36-8
nsc 640116
9-acridinamine, n-(3-(2-nitro-1h-imidazol-1-yl)propyl)-, monohydrochloride
n-(3-(2-nitro-1h-imidazol-1-yl)propyl)-9-acridinamine monohydrochloride
nla 1
nla-1
nsc-640116
CHEMBL541282
SCHEMBL8909002
9-[3-(2-nitro-1-imidazolyl) propylamino]acridine hydrochloride
n-[3-(2-nitroimidazol-1-yl)propyl]acridin-9-amine;hydrochloride
DTXSID70930840
n-[3-(2-nitro-1h-imidazol-1-yl)propyl]acridin-9(10h)-imine--hydrogen chloride (1/1)
55KV4C37DS
n-[3-(2-nitro-1h-imidazol-1-yl)propyl]-9-acridinamine hydrochloride (1:1)
9-acridinamine, n-[3-(2-nitro-1h-imidazol-1-yl)propyl]-, hydrochloride (1:1)
AKOS040753292

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay ID	Title	Year	Journal	Article
AID21048	Partition coefficient in octanol/water	2004	Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6	Synthesis of novel 2-nitroimidazole-tethered tricyclic quinolines, bearing a second heteroatom, and their in vitro evaluation as hypoxia-selective cytotoxins and radiosensitizers.
AID228276	Concentration required to reduce fluorescence in ethidium bromide displacement assay using EB-DNA complex	2004	Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6	Synthesis of novel 2-nitroimidazole-tethered tricyclic quinolines, bearing a second heteroatom, and their in vitro evaluation as hypoxia-selective cytotoxins and radiosensitizers.
AID216742	Cytotoxicity of compound was measured against suspended V79 cells under aerobic conditions in clonogenic assay	2004	Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6	Synthesis of novel 2-nitroimidazole-tethered tricyclic quinolines, bearing a second heteroatom, and their in vitro evaluation as hypoxia-selective cytotoxins and radiosensitizers.
AID216743	Cytotoxicity of compound was measured against suspended V79 cells under hypoxic conditions in clonogenic assay	2004	Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6	Synthesis of novel 2-nitroimidazole-tethered tricyclic quinolines, bearing a second heteroatom, and their in vitro evaluation as hypoxia-selective cytotoxins and radiosensitizers.
AID216883	In vitro therapeutic index of compound was measured inV79 cells	2004	Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6	Synthesis of novel 2-nitroimidazole-tethered tricyclic quinolines, bearing a second heteroatom, and their in vitro evaluation as hypoxia-selective cytotoxins and radiosensitizers.
AID231440	Ratio (HS) of CT50 values in aerobic condition to hypoxic condition (in N2 presence) given as CT50(A)/CT50(H)	2004	Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6	Synthesis of novel 2-nitroimidazole-tethered tricyclic quinolines, bearing a second heteroatom, and their in vitro evaluation as hypoxia-selective cytotoxins and radiosensitizers.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	4 (80.00)	18.2507
2000's	1 (20.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	20.04 (24.57)
Research Supply Index	1.79 (2.92)
Research Growth Index	4.20 (4.65)
Search Engine Demand Index	15.26 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (20.04)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
tacrine Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.. tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.	1.98	1	acridines; aromatic amine	EC 3.1.1.7 (acetylcholinesterase) inhibitor
lomustine [no description available]	1.98	1	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
azomycin azomycin: RN given refers to parent cpd with specified locant; structure	2.89	4	C-nitro compound; imidazoles	antitubercular agent
9-(3-(2-nitro-1-imidazolyl)propylamino)-1,2,3,4-tetrahydroacridine 9-(3-(2-nitro-1-imidazolyl)propylamino)-1,2,3,4-tetrahydroacridine: RN refers to HCl; structure given in first source	2.4	2

chemdatabank.com